Latest Hospitality News

Orthocell has appointed a second Canadian distributor for its nerve repair device Remplir™, achieving full national coverage and setting the stage for initial sales this quarter.

Imricor Medical Systems and Amsterdam UMC have completed the first-ever ischemic ventricular tachycardia ablation fully guided by real-time MRI, marking a major advance in cardiac electrophysiology.

Orthocell has completed its first Remplir™ surgical case in Hong Kong, marking a pivotal step in its Asian commercialisation strategy. The launch at the Hong Kong Orthopaedic Association Congress and partnership with MontsMed set the stage for broader regional growth.

Anteris Technologies has secured FDA approval to commence its pivotal PARADIGM clinical trial, testing its innovative DurAVR Transcatheter Heart Valve against established devices in patients with severe aortic stenosis.

HealthCo Healthcare & Wellness REIT confirms full collection of deferred and current rent from Healthscope, while advancing conditional agreements with alternative tenants for its hospital portfolio.

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

Adherium Limited reports a strong quarter with a 55% increase in device shipments and groundbreaking clinical results from its iCARE study, alongside securing over $2.6 million in post-quarter funding.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.